Levetiracetam in social phobia: a placebo controlled pilot study
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
While serotonergic antidepressants are now established as first-line pharamcotherapy for generalized social anxiety disorder (SAD), other agents with different mechanisms have shown promise in treating SAD. The aim of this pilot study is to examine the efficacy and safety of levetiracetam (LEV), an anticonvulsant with calcium channel modulating properties, in treating SAD. Adult outpatients meeting DSM-IV criteria for SAD were randomly assigned (2:1) to double-blind treatment with either LEV (500-3000mg/day) or placebo (PBO) for 7 weeks. The primary outcome measures were the change from baseline in the Brief Social Phobia Scale (BSPS) and response using the Clinical Global Impression of Improvement scale (CGI-I). The mean (SD) BSPS scores at baseline and endpoint were 45.4 (9.7) and 31.2 (19.7) for LEV (n 9), compared to 43.5 (8.4) and 37.8 (19.9) for PBO (n 7) (ITT; ns). Rates of response were 22% for LEV and 14% for PBO using the CGI-I. Using a BSPS response criterion (>30% reduction), response rates were 44% for LEV and 14% for PBO. The effect sizes of LEV relative to PBO were 0.33 for the BSPS and 0.50 for the LSAS. In summary, the results of this study, while negative on the pre-defined measures, suggest promise for LEV as a new treatment of SAD. Further work should be carried out with larger sample sizes and optimal dosing strategies of the drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Psychometric properties of the Social Phobia Inventory (SPIN): New self-rating scale
Connor, K. M., Davidson, J. R. T., Churchill, L. E., Sherwood, A., Weisler, R. H., & Foa, E. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.4.379 · Cited by 1,624 · cited 4×
“No differences were observed on the measures of social anxiety, including the BSPS (primary outcome measure), LSAS and the self-rate SPIN (Table 1).”
MethodSelf-citationPsychometric properties of the Liebowitz Social Anxiety Scale
HEIMBERG, R. G., HORNER, K. J., JUSTER, H. R., SAFREN, S. A., BROWN, E. J., SCHNEIER, F. R., & LIEBOWITZ, M. R. (1999) · Psychological Medicine · doi:10.1017/s0033291798007879 · Cited by 968 · cited 7×
“For the BSPS, ES 0.33, while on the LSAS, ES 0.50.”
MethodInfluentialRosnow, R. L., & Rosenthal, R. (1996) · Psychological Methods · doi:10.1037/1082-989x.1.4.331 · Cited by 761 · cited 2×
“The pooled standard deviation (Rosnow and Rosenthal, 1996) is the root mean square of the two standard deviations (Cohen, 1988).”
BackgroundFluoxetine, Comprehensive Cognitive Behavioral Therapy, and Placeboin Generalized Social Phobia
Davidson, J. R. T., Foa, E. B., Huppert, J. D., Keefe, F. J., Franklin, M. E., Compton, J. S., Zhao, N., Connor, K. M., Lynch, T. R., & Gadde, K. M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.10.1005 · Cited by 415 · cited 1×
“Response rates were measured using the CGI-I and BSPS, with BSPS response based upon a greater than 30% reduction in the BSPS score from baseline, a criterion which we have previously used (Davidson et al., 2004).”
MethodSelf-citationPande, A. C., Feltner, D. E., Jefferson, J. W., Davidson, J. R. T., Pollack, M., Stein, M. B., Lydiard, R. B., Futterer, R., Robinson, P., Slomkowski, M., et al. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000117423.05703.e7 · Cited by 227 · cited 2×
“Among these alternatives, the anticonvulsants carry some appeal, in that positive placebo-controlled data already exist for the alpha2-delta calcium channel modulators gabapentin and pregabalin (Pande et al., 1999; Pande et al., 2004).”
BackgroundSelf-citationPharmacotherapy of social anxiety disorder
Blanco, C., Antia, S. X., & Liebowitz, M. R. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01294-x · Cited by 88
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“In RCTs there was no evidence of benefits with the betablockers atenolol (Level 1, negative) [461,484] or propranolol (Level 2, negative) [488], or for the following treatments: buspirone [383,485], levetiracetam [478-480] (both Level 1, negative), or quetiapine (Level 2, negative) [494,495].”
BackgroundPharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
“Levetiracetam, approved only for seizure disorders (and with unclear mechanism, but thought to reduce hyperexcitation of brain cells through binding to the synaptic vesicle protein SV2A, but to not interfere with normal electrical activity) (51), has undergone two RCTs for SAD in which the medication failed to show a…”
BackgroundCotrafficking of SV2 and synaptotagmin at the synapse
Yao, J., Nowack, A., Kensel-Hammes, P., Gardner, R. G., & Bajjalieh, S. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4781-09.2010 · Cited by 164
“, 2007), and which also shows promise for the treatment of anxiety disorders (Zhang et al., 2005; Kinrys et al., 2006, 2007), pain (Price, 2004; Dunteman, 2005; Enggaard et al.”
BackgroundMethodSV2 regulates neurotransmitter release via multiple mechanisms
Nowack, A., Yao, J., Custer, K. L., & Bajjalieh, S. M. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00259.2010 · Cited by 138
Pollack, M. H., Jensen, J. E., Simon, N. M., Kaufman, R. E., & Renshaw, P. F. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.11.023 · Cited by 112
“, 2003) and in small open and controlled trials in humans with SAD (Simon et al., 2004; Zhang et al., 2005), as well as posttraumatic stress disorder (Kinrys et al.”
Metadata
- Authors
- Zhang, W., Connor, K. M., & Davidson, J. R. T.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2005-09
- Volume
- 19
- Issue
- 5
- Pages
- 551-553
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2033568747
- Cited by
- 60
- References
- 6
- FWCI
- 6.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Levetiracetam in social phobia: a placebo controlled pilot study. https://app.cochat.ai/papers/10.1177/0269881105056526
- The paper
- Zhang, W., Connor, K. M., & Davidson, J. R. T. (2005). Levetiracetam in social phobia: a placebo controlled pilot study. Journal of Psychopharmacology. https://doi.org/10.1177/0269881105056526
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.